Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 13/20 | 0.60 |
| ▸ | CTSB | P07858 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | CASP7 | P55210 | 9/20 | 0.47 |
| ▸ | CASP1 | P29466 | 6/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | CASP9 | P55211 | 4/20 | 0.46 |
| ▸ | CASP4 | P49662 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962153 | 0.91 | CASP3 (0.59) | CASP3CTSBCTSKCASP7CASP1 | |
| SCHEMBL9961981 | 0.90 | CASP3 (0.64) | CASP3CTSBCTSKCASP7CASP1 | |
| SCHEMBL9962261 | 0.85 | CASP3 (0.53) | CASP3CTSBCTSKCASP7CASP1 | |
| SCHEMBL7887362 | 0.83 | CASP3 (0.61) | CASP3CTSBCTSKCASP7CASP1 | |
| SCHEMBL9962213 | 0.83 | CASP3 (0.84) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL9962268 | 0.82 | CASP3 (0.69) | CASP3CTSBCTSKCASP7CASP1 | |
| SCHEMBL9961959 | 0.80 | CASP3 (0.62) | CASP3CTSBCTSKCASP7CASP1 | |
| SCHEMBL7888191 | 0.80 | CTSK (0.53) | CASP3CTSBCTSKCASP1REN | |
| SCHEMBL7887374 | 0.80 | CASP3 (0.62) | CASP3CTSBCTSKCASP7CASP1 | |
| SCHEMBL9962256 | 0.80 | CTSK (0.59) | CASP3CTSBCTSKCASP1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | CASP3 6/4885CTSB 44/4885CTSK 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.